Briakinumab Biosimilar, Anti-human IL-12 / IL-23 Monoclonal Antibody | C041P

Catalog No.	C041P
Product Name	Briakinumab Biosimilar, Anti-human IL-12 / IL-23 Monoclonal Antibody | C041P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin 12, IL-12, IL12, IL23, IL-23, p70, IL12B, IL-12p40, Interleukin 23
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The anti-human IL-12 / IL-23 monoclonal antibody briakinumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade briakinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by briakinumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade briakinumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Briakinumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C041P: Briakinumab Biosimilar, Anti-human IL-12 / IL-23 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

What is Briakinumab Biosimilar research grade? Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Briakinumab Biosimilar uses the same protein sequences as the therapeutic antibody briakinumab.

Syd Labs also provides the following anti-IL antibody biosimilar proteins:
Pascolizumab Biosimilar, research grade, anti-human IL-4 monoclonal antibody
Sarilumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Secukinumab Biosimilar, research grade, anti-human IL-17/IL-17a monoclonal antibody
Tocilizumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Ustekinumab Biosimilar, research grade, anti-human IL-12/IL-23 monoclonal antibody

Please remember our product information: Briakinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody: C041P Syd Labs

No more offers for this product!